In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1713i ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Sarcoma, Synovial. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Afamitresgene autoleucel (Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen. It is the first gene therapy to be approved in the US for treatment of synovial sarcoma. Accelerated approval of the immunotherapy was based on the overall response rate and duration of response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1713i
Vancouver
In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1713i
BibTeX
@article{euvimed2024,
title = {In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1713i}
}
EUVIMED